Boyds has welcomed Laura Erwin as Senior Clinical and Regulatory Medical Writer to the team bolstering Boyds’ regulatory writing expertise.
Laura is a highly resourceful regulatory affairs consultant and brings combined experience as a medical writer, strategic planner and project manager. She is experienced in writing and editing a wide range of regulatory documents for biotech and pharmaceutical companies and has particular expertise in authoring protocols and CSRs as well as writing regulatory documents such as New Drug Applications (NDAs) and Orphan Drug Designations (ODDs).
Harriet Gray Stephens, Medical Director at Boyds, says: “We are thrilled to welcome Laura to the team, and we are looking forward to the great contribution she will make to our client projects and the wider team. We have been experiencing a steep increase in demand for our expert regulatory and clinical writing support, and Laura brings a wealth of expertise in regulatory writing which will benefit our clients. She will be an integral part of the team and will also work closely with our award-winning regulatory team.”
Laura adds: “I’m delighted to join Boyds’ expert team. I look forward to meeting with existing clients and contributing immediately to ongoing projects and connecting with future clients to explore new opportunities.”
Laura completed her post-doctoral research at McLean Hospital and Harvard Medical School. Before starting her career in regulatory, she lobbied on Capitol Hill for scientific funding with ASPET and worked with Americans for Medical Progress as a BRAD Fellow. Prior to joining Boyds, she worked at Allucent, as a Regulatory Affairs Scientist, and at Dunn Regulatory Associates as a Regulatory Affairs Consultant.
For more information about regulatory and medical writing services at Boyds, please click here.
